Impact of CYP2A6 Gene Polymorphism on the Efficacy and Safety of S-1 Therapy in Patients with Gastric Cancer: A Systematic Review and Meta-Analysis.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-04-10 DOI:10.1159/000538769

Tao Dong, Yuanyuan Gu

{"title":"Impact of CYP2A6 Gene Polymorphism on the Efficacy and Safety of S-1 Therapy in Patients with Gastric Cancer: A Systematic Review and Meta-Analysis.","authors":"Tao Dong, Yuanyuan Gu","doi":"10.1159/000538769","DOIUrl":null,"url":null,"abstract":"INTRODUCTION\nThe relationship of CYP2A6 polymorphisms with S-1 therapy outcomes in gastric cancer is unclear. This review aims to assess the association between CYP2A6 gene polymorphisms (CYP2A6*4, *7, *9, *10) and S-1 therapy outcomes in gastric cancer, aiming to identify predictive markers for S-1 efficacy and adverse reactions.\n\n\nMETHODS\nWe searched seven databases, using random or fixed effect models to calculate hazard ratio (HR) and 95% confidence interval (CI) based on study heterogeneity.\n\n\nRESULTS\nA total of 1143 articles were retrieved from multiple online databases as of March 28, 2023. After screening, seven articles containing seven investigations were included in the meta-analysis. Our results revealed a significant association between the CYP2A6 polymorphism site and the overall survival (OS) of V/V patients compared to W/W or W/V patients (HR=2.73, 95%CI:1.45-5.14, P=0.002). S-1 was more beneficial for W/W or W/V patients than V/V patients in terms of Progression-Free Survival (PFS) (HR=3.15,95%CI:1.47-6.75, P=0.003). There was no association between CYP2A6 polymorphism and hematological adverse reactions (OR=0.52, 95%CI: 0.23-1.15, P=0.104).\n\n\nCONCLUSION\nCYP2A6 polymorphisms correlate with S-1 efficacy (OS, PFS) in gastric cancer, suggesting their potential as predictive markers. However, the generalizability of findings is limited by the small number of studies from Eastern countries and variations in chemotherapy regimens and detection methods. Further large-scale studies are needed to confirm these associations.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":"362 2","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000538769","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION The relationship of CYP2A6 polymorphisms with S-1 therapy outcomes in gastric cancer is unclear. This review aims to assess the association between CYP2A6 gene polymorphisms (CYP2A6*4, *7, *9, *10) and S-1 therapy outcomes in gastric cancer, aiming to identify predictive markers for S-1 efficacy and adverse reactions. METHODS We searched seven databases, using random or fixed effect models to calculate hazard ratio (HR) and 95% confidence interval (CI) based on study heterogeneity. RESULTS A total of 1143 articles were retrieved from multiple online databases as of March 28, 2023. After screening, seven articles containing seven investigations were included in the meta-analysis. Our results revealed a significant association between the CYP2A6 polymorphism site and the overall survival (OS) of V/V patients compared to W/W or W/V patients (HR=2.73, 95%CI:1.45-5.14, P=0.002). S-1 was more beneficial for W/W or W/V patients than V/V patients in terms of Progression-Free Survival (PFS) (HR=3.15,95%CI:1.47-6.75, P=0.003). There was no association between CYP2A6 polymorphism and hematological adverse reactions (OR=0.52, 95%CI: 0.23-1.15, P=0.104). CONCLUSION CYP2A6 polymorphisms correlate with S-1 efficacy (OS, PFS) in gastric cancer, suggesting their potential as predictive markers. However, the generalizability of findings is limited by the small number of studies from Eastern countries and variations in chemotherapy regimens and detection methods. Further large-scale studies are needed to confirm these associations.

查看原文本刊更多论文

CYP2A6基因多态性对胃癌患者S-1疗法疗效和安全性的影响：系统回顾与元分析》。

引言 CYP2A6基因多态性与胃癌S-1治疗结果的关系尚不明确。本综述旨在评估CYP2A6基因多态性（CYP2A6*4、*7、*9、*10）与胃癌S-1治疗结果之间的关系，旨在确定S-1疗效和不良反应的预测标志物。结果截至2023年3月28日，从多个在线数据库中共检索到1143篇文章。经过筛选，包含七项研究的七篇文章被纳入荟萃分析。我们的结果显示，与 W/W 或 W/V 患者相比，CYP2A6 多态性位点与 V/V 患者的总生存率（OS）之间存在显著关联（HR=2.73，95%CI:1.45-5.14，P=0.002）。就无进展生存期（PFS）而言，S-1对W/W或W/V患者的益处大于V/V患者（HR=3.15，95%CI：1.47-6.75，P=0.003）。结论CYP2A6多态性与S-1在胃癌中的疗效（OS、PFS）相关，表明其具有作为预测标记物的潜力。然而，由于来自东方国家的研究较少，且化疗方案和检测方法存在差异，研究结果的推广性受到了限制。还需要进一步的大规模研究来证实这些关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464

期刊介绍： ACS Applied Bio Materials is an interdisciplinary journal publishing original research covering all aspects of biomaterials and biointerfaces including and beyond the traditional biosensing, biomedical and therapeutic applications. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrates knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important bio applications. The journal is specifically interested in work that addresses the relationship between structure and function and assesses the stability and degradation of materials under relevant environmental and biological conditions.